Clinical trials: Insufficient Metabolic Control
Type 2 Diabetes
Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes
The purpose of this study is to learn if BMS-477118 (Saxagliptin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug…
- Trial name
- NCT01619059
- Testing
- Saxagliptin, Dapagliflozin, Metformin IR
- Where
- 83 sites in United States, Canada and 7 more
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment
All the guidelines suggest that metformin as the basis of type 2 diabetes medication, and evidence is sufficient.At the same time the basal insulin injection once a day are more and more widely used in diabetes patients in China.
- Trial name
- NCT02026310
- Testing
- glimepiride, glargine and metformin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Qifu Li
Diabetes Type 2
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control.
- Trial name
- NCT06354660
- Testing
- Retatrutide
- Where
- 48 sites in United States, India and 2 more
- Volunteers
- 537 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin
This is a randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of evogliptin after oral administration in patients with type 2 diabetes who have inadequate glycemic control…
- Trial name
- NCT02946541
- Testing
- evogliptin 5mg
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Dong-A ST Co., Ltd.
Type 2 Diabetes
Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin
This study is being carried out to see if Dapagliflozin in addition to insulin is effective and safe in treating patients with type 2 diabetes when compared to placebo (identical looking inactive treatment) in addition to insulin
- Trial name
- NCT00673231
- Testing
- Dapagliflozin
- Where
- 92 sites in United States, Austria and 11 more
- Volunteers
- 1,240 people
- Sponsor
- AstraZeneca
Diabetes Type 2
Safety Study of BMS-770767 in Subjects With Type 2 Diabetes
The purpose of this study is to determine if BMS-770767 is safe, well tolerated, measure its levels in the blood (pharmacokinetics), and measure the levels of chemicals (biomarkers) that may be affected by this drug…
- Trial name
- NCT01046422
- Testing
- BMS-770767, Metformin
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 76 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes (T2DM)
A Study of BGM0504 in Early T2DM With Obesity
This trial is conducted in China. The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise.
- Trial name
- NCT07743983
- Testing
- BGM0504, semaglutide
- Where
- China
- Volunteers
- 372 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Type 2 Diabetes Mellitus, High HbA1c Level
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
This study intends to compare the efficacy and safety of dapagliflozin versus placebo in patients with type 2 diabetes who have inadequate glycaemic control on a background combination of metformin and sulfonylurea.
- Conditions
- Type 2 Diabetes Mellitus, High HbA1c Level, Inadequate Glycaemic Control
- Trial name
- NCT01392677
- Testing
- dapagliflozin
- Where
- 42 sites in Canada, Czechia and 4 more
- Volunteers
- 311 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
This study is a multicenter, randomized, open-label, parallel-group, semaglutide injection-controlled clinical trial. It aims to evaluate the non-inferiority of UBT251 Injection in glycemic control compared with Semaglutide…
- Trial name
- UNIGUIDE-2 (NCT07653477)
- Testing
- UBT251 Injection 2.0 mg group, UBT251 Injection 4.0 mg group, UBT251 Injection 6.0 mg group
- Where
- China
- Volunteers
- 956 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Type 2 Diabetes Mellitus
Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin
This study is intended to assess the effect on HbA1c of different dose regimens of LX4211 in combination with metformin in subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin monotherapy.
- Trial name
- NCT01376557
- Testing
- 75 mg LX4211, 200 mg LX4211, 400 mg LX4211
- Where
- 56 sites in United States
- Volunteers
- 299 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the effects of dapagliflozin on kidney function, as assessed by glomerular filtration rate.
- Trial name
- NCT00976495
- Testing
- Dapagliflozin, Hydrochlorothiazide
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 154 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy
To assess the efficacy of treatment with sitagliptin or dapagliflozin or lobeglitazone in type 2 diabetes mellitus patients, who had inadequate glycemic control even though use of two drug combination therapy with glimepiride and…
- Trial name
- NCT02338921
- Testing
- Sitagliptin, Dapagliflozin, Lobeglitazone
- Where
- South Korea
- Volunteers
- 78 people
- Sponsor
- Seoul National University Bundang Hospital
Gout
Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients
The purpose of this study is to evaluate the efficacy, safety and tolerability of MBX-102 in combination with allopurinol compared to allopurinol alone when administered orally once a day for four weeks to gout patients with an…
- Trial name
- NCT01399008
- Testing
- Arhalofenate, Allopurinol, Colchicine
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Type 2 Diabetes
Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
This study evaluates the efficacy and safety of adding the SGLT-2 inhibitor DA5221-T to the combination therapy of DA5221-B1 and the DPP-4 inhibitor DA5221-B2 in patients with type 2 diabetes who have inadequate blood glucose…
- Trial name
- NCT06290349
- Testing
- DA5221-T1, DA5221-T2, DA5221-B1
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Dong-A ST Co., Ltd.
Diabete Mellitus
Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
This study is a multicenter, double-blind, active-controlled, randomized, parallel clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing BT-1 and BT-2 combination therapy in patients with type 2…
- Trial name
- NCT07239440
- Testing
- DA-2811, DA-2811-C
- Where
- South Korea
- Volunteers
- 288 people
- Sponsor
- Dong-A ST Co., Ltd.
Type 2 Diabetes Mellitus
A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)
The purpose of this study is to assess the effect of the addition of sitagliptin (administered as MK-0431A or MK-0431A XR) relative to the addition of placebo on glycated hemoglobin (A1C), and the safety and tolerability of the…
- Trial name
- NCT01760447
- Testing
- Sitagliptin plus metformin, Metformin, Sitagliptin plus metformin XR
- Volunteers
- 223 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
This study evaluates the addition of dapagliflozin in the treatment of type 2 diabetes with metformin and evogliptin combination therapy.
- Trial name
- NCT04356742
- Testing
- Dapagliflozin 10mg, Evogliptin 5mg, Metformin≥1000mg
- Where
- South Korea
- Volunteers
- 198 people
- Sponsor
- Dong-A ST Co., Ltd.
Type 2 Diabetes Mellitus
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
The purpose of this study is to investigate the effect of bexagliflozin compared to glimepiride as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02769481
- Testing
- Bexagliflozin, Glimepiride
- Where
- 45 sites in United States, Germany and 2 more
- Volunteers
- 426 people
- Sponsor
- Theracos
Type 2 Diabetes
Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS -512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated Hemoglobin (Hemoglobin A1c) in patients with type 2…
- Trial name
- NCT01606007
- Testing
- Saxagliptin, Metformin XR, Dapagliflozin
- Where
- 139 sites in United States, Canada and 6 more
- Volunteers
- 1,282 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress
This research will focus on the effect of Sitagliptin on 24 hour glycemic excursion and improvement of oxidative stress markers compared to long acting sulphonylurea Glimepiride in type 2 diabetic patients with inadequate…
- Trial name
- NCT00699322
- Testing
- Sitagliptin, Glimepiride
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- The Catholic University of Korea